Delivering Cancer Treatment Inside Cells – Nature Oncogene

June 2018 Quarterly Operational Update and Appendix 4C

Achievement of Major Milestone – In vivo Cre Delivery

Successful In-vivo Results Peptide Vaccine T-Cell Expansion

Peer Reviewed Journal Publication

Change in Substantial Holding

Chief Executive Officer Employment Terms

Investor Presentation May 2018

Final Director’s Interest Notice

March Quarter Investor Call Details

March 2018 Operational Update and Cashflow

Initial and Change of Director’s Interest Notices

Changes to Board and Management

Notice of Change of Interest of Substantial Shareholder

Notice of Change of Interest of Substantial Shareholder

Phylogica Appoints New Scientific Advisory Board Member

PYC Pivot to Platform – BioShowcase Presentation

FPP Results Effective in Delivering Peptide Cancer Vaccine

Phylogica Strategic Update – Pivot to Platform

Final Director’s Interest Notice

Company Presentation – 2017 Annual General Meeting

Chairman’s Address – 2017 Annual General Meeting

Paul Watt Joins Phylogica Scientific Advisory Board

Company Presentation – BIO Europe November 2017

Corporate Governance Statement

Annual Report to shareholders

Becoming a substantial holder

Appointment of Non-Executive Director

Investor Presentation – October 2017

June 2017 Annual Financial Statements

Finance News Network Interview with the CEO

Sydney Investor Presentation

New Delivery Vehicles Show Improved Performance Inside Cells

Investor Presentation

Phylogica Investor Briefing – August 2017 Amended

Appendix 4C – quarterly

S 708A cleansing notice for option exercise

Application for listing upon option exercise

Appendix 3B option exercise

S708 Cleansing Notice option issue

Executive Director Remuneration

Becoming a substantial holder

Ceasing to be a substantial holder

Change in substantial holding

Change of Director’s Interest Notice

CEO and CSO Appointments

Share issue S708A cleansing notice

Application for listing $5m placement

Change of Director’s Interest Notice

S708A notice upon the issue of shares

S708 Notice for issue of shares

Appendix 3B application for listing

Final Director’s Interest Notice

Initial Director’s Interest Notice (two directors)

Operational Update March Quarter

Resignation of Secretary

Operational Update

Genentech extends research collaboration period

NHMRC Grant Awarded to Collaborators

AGM Presentation to Shareholders

Chair’s Address to Shareholders

Becoming a substantial holder

Appendix 4C – quarterly

Notice of Annual General Meeting/Proxy Form

Annual Report to shareholders

Change of Director’s Interest Notice

Change of Director’s Interest Notice

Initial Director’s Interest Notice

Director Appointment

Cell-Penetrating Phylomers Improve Delivery of Drugs

Conference Presentation

Appendix 4C – Quarterly

Chair Appointment and Director Resignation

Final Director’s Interest Notice

Half Yearly Report and Accounts

Appendix 4C – Quarterly

Director Appointment

Initial Director’s Interest Notice

Combination Therapy Escalates Potency of Phylogica Peptides Against MYC-Driven Cancer

Shareholder Briefings

AGM Presentation

Change of Director’s Interest Notice

Proprietary Anti-Cancer Drug Candidates

Corporate Governance Statement

Animal Model Cancer Studies

Appendix 4C – Quarterly

Annual Report to Shareholders